Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cang-Ai Volatile Oil Inhalation for Depression
NCT05251779Phase 1Unknown
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised trial of Cang-ai Volatile Oil in major depressive disorder (MDD) (2 arms). Primary endpoints: functional near-infrared spectroscopy at 28 days and 24-item Hamilton Depression Inventory at 28 days. Status: unknown.
02
Drugs
Cang-ai Volatile Oil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05251779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251779.